Cyclosporine

Generic Name
Cyclosporine
Brand Names
Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
Drug Type
Small Molecule
Chemical Formula
C62H111N11O12
CAS Number
59865-13-3
Unique Ingredient Identifier
83HN0GTJ6D
Background

Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).

Indication

Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).

Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.

A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.

Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.

Associated Conditions
Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
Associated Therapies
-

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2006-11-30
Last Posted Date
2016-11-22
Lead Sponsor
Wills Eye
Target Recruit Count
43
Registration Number
NCT00405431
Locations
🇺🇸

Wills Eye Glaucoma Service, Philadelphia, Pennsylvania, United States

Irinotecan With or Without Panitumumab or Cyclosporine in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Fluorouracil

Phase 3
Completed
Conditions
First Posted Date
2006-10-19
Last Posted Date
2022-06-01
Lead Sponsor
University of Leeds
Target Recruit Count
1198
Registration Number
NCT00389870
Locations
🇬🇧

James Cook University Hospital, Middlesbrough, England, United Kingdom

🇬🇧

Royal Marsden - Surrey, Sutton, England, United Kingdom

🇬🇧

Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom

and more 30 locations

Methods to Enhance the Safety and Effectiveness of Stem Cell Transplants

First Posted Date
2006-09-20
Last Posted Date
2021-06-16
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
116
Registration Number
NCT00378534
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

The Effectiveness of Lower Cyclosporine Doses for Psoriasis

Phase 2
Withdrawn
Conditions
Interventions
First Posted Date
2006-09-18
Last Posted Date
2014-11-21
Lead Sponsor
University of Rochester
Registration Number
NCT00377325
Locations
🇺🇸

University of Rochester Department of Dermatology, Rochester, New York, United States

Switch From Tacrolimus to Cyclosporin in the Treatment of Recurrent Hepatitis C After Liver Transplantation

First Posted Date
2006-09-13
Last Posted Date
2012-03-02
Lead Sponsor
Rennes University Hospital
Target Recruit Count
11
Registration Number
NCT00375895
Locations
🇫🇷

Chirurgie Générale - Hôpital de la Conception, Marseille, France

🇫🇷

Service d'Hépato-gastro-entérologie - Hôpital Saint Eloi, Montpellier, France

🇫🇷

Service d'Hépato-gastro-entérologie - Hôpital de Rangueil, Toulouse, France

and more 10 locations

Effect of Cyclosporine Therapy on Gene Expression in Patients With Large Granular Lymphocyte Leukemia

First Posted Date
2006-08-15
Last Posted Date
2015-07-21
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
5
Registration Number
NCT00363779
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath